Patents Assigned to GLENMARK
  • Anti-alpha2 integrin antibodies and their uses
    Patent number: 8759009
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: June 24, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Antibodies that bind to OX40 and their uses
    Patent number: 8748585
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: June 10, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID
    Publication number: 20140148423
    Abstract: The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a glucocorticoid.
    Type: Application
    Filed: July 23, 2012
    Publication date: May 29, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima Khairatakar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Anil Hari Kadam, Vikram Bhosale
  • FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS
    Publication number: 20140128603
    Abstract: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 8, 2014
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Sachin Sundarlal Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha Parag Patil, Ashok Bhausaheb Kadam, Vishal Govindrao Deshmukh, Sachin Vasantrao Dhone, Rajendra Prakash Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
  • PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A BETA-2 AGONIST
    Publication number: 20140107113
    Abstract: The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a beta-2 adrenergic receptor agonist (“beta-2 agonist”).
    Type: Application
    Filed: June 21, 2012
    Publication date: April 17, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Anil Hari Kadam, Thamil Selvan Vaiyapuri
  • Humanized antibodies that bind to CD19 and their uses
    Patent number: 8679492
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 25, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Stable fixed dose topical formulation
    Patent number: 8673356
    Abstract: The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Glenmark Pharmaceuticals Limited
    Inventors: Ulhas Rameshchandra Dhuppad, Nitin Babulal Bhamre, Sunil Sudhakar Chaudhari, Girish Ramakrishna Trivedi, Akhilesh Dayanand Sharma, Prashant Dongre
  • STABLE PHARMACEUTICAL COMPOSITION OF SAXAGLIPTIN
    Publication number: 20140072628
    Abstract: Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 13, 2014
    Applicant: Glenmark Generics Ltd.
    Inventors: Atul Kaushik, Arra Ganga Srinivas, Kamal Mehta
  • Hetero-Dimeric Immunoglobulins
    Publication number: 20140066599
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Application
    Filed: March 23, 2012
    Publication date: March 6, 2014
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
  • 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS
    Publication number: 20140051667
    Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 20, 2014
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
  • 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS
    Publication number: 20140045865
    Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
  • Fused pyrimidine-dione derivatives as TRPA1 modulators
    Patent number: 8623880
    Abstract: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: January 7, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Sachin Sundarlal Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha Parag Patil, Ashok Bhausaheb Kadam, Vishal Govindrao Deshmukh, Sachin Vasantrao Dhone, Rajendra Prakash Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
  • Process for the preparation of strontium ranelate
    Patent number: 8624041
    Abstract: A process for the preparation of strontium ranelate or a hydrate thereof is provided comprising (a) reacting a tetraester compound of Formula II: wherein R, R1, R2, and R3 are independently a linear or branched C1-C6 alkyl group or a substituted or unsubstituted C3-C12 cyclic group, in the presence of a lithium base and in a solvent with an inorganic acid salt of strontium.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: January 7, 2014
    Assignee: Glenmark Generics Ltd.
    Inventors: Bobba Venkata Siva Kumar, Kosampally Srinivas, Sanjay Anantha Kale, Nitin Sharad Chandra Pradhan
  • Expression Cassette
    Publication number: 20130344604
    Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.
    Type: Application
    Filed: December 5, 2012
    Publication date: December 26, 2013
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Christel Aebischer-Gumy, Martin Bertschinger, Daniel Luescher, Pierre Moretti
  • 2-amino-4-arylthiazole compounds as TRPA1 antagonists
    Patent number: 8592398
    Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 26, 2013
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
  • Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators
    Patent number: 8575178
    Abstract: The present invention is related to novel isothiazolo[3,4-d]pyrimidinedione and isothiazolo[5,4-d]pyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 5, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
  • Processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of PDE IV inhibitors
    Patent number: 8524905
    Abstract: The present invention relates to novel processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, which is a novel and useful intermediate for preparing compounds with PDE4 inhibitory activity, such as 3,5-dichloro-4-(6-difluoromethoxybenzo[4,5]furo[3,2-c]pyridin-9-ylcarboxamido)-1-pyridiniumolate.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: September 3, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant Atmaram Gharat, Jitendra Maganbhai Gajera, Sandip Damodar Patil, Suresh M. Kadam
  • Tricyclic compounds as mPGES-1 inhibitors
    Patent number: 8519149
    Abstract: The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: August 27, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Lakshminarayana Narayana, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Fused pyrimidineone compounds as TRPV3 modulators
    Patent number: 8518955
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 27, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: V. S. Prasada Rao Lingam, Sachin Sundarlal Chaudhari, Abraham Thomas, Neelima Khairatkar-Joshi, Vidya Ganpati Kattige
  • BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
    Publication number: 20130210844
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 15, 2013
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventor: Glenmark Pharmaceuticals S.A.